Biopsy-Proven Pulmonary Tumors Detected by LDCT: A 10-Year Single-Center Study of Growth Patterns and Diagnostic Pitfalls

TL;DR

A 10-year study found that LDCT screening can detect lung tumors but also leads to challenges in distinguishing benign from malignant tumors, with some benign tumors showing growth and a notable false-negative biopsy rate.

Contribution

This study provides insights into the growth patterns and diagnostic challenges of benign and malignant lung tumors detected via LDCT screening.

Findings

34% of biopsied tumors were benign, with fibrosis and anthracosis being common findings.

Benign tumors showed faster growth rates and shorter volume doubling times compared to malignant tumors.

CT-guided biopsy had a 23% false-negative rate and a 78% negative predictive value.

Abstract

Low-dose computed tomography (LDCT) reduces lung cancer mortality but may lead to increased resection of benign tumors. We aimed to characterize growth patterns, pathologic diagnoses, diagnostic timelines, and CT-guided biopsy accuracy in screening-detected lung tumors.

We retrospectively analyzed LDCT screening data from 6,997 participants at Taipei Tzu Chi Hospital (2013-2018) with follow-up through 2023. Clinical, radiologic, and pathological features of biopsied lung tumors were evaluated. Volume doubling time (VDT) was calculated for progressive lesions.

Among the 128 patients who underwent biopsy, 84 were diagnosed with lung cancer, resulting in a detection rate of 1.2%. Of these, 86% were stage 0-I, and 95% were adenocarcinomas. Of the 157 biopsied tumors, 34% were benign. The most common benign pathological finding was fibrosis, followed by anthracosis. Lobulation and subsolid attenuation were significantly associated with malignancy. Time to diagnosis did not differ significantly between benign and malignant tumors (HR = 1.1, p = 0.53). Notably, 7% of benign tumors showed interval growth and 13% were detected de novo. Benign tumors exhibited a faster growth rate (3.8 vs. 1.5 mm/year, p = 0.28) and shorter VDT (347 vs. 565 days, p = 0.14) than malignant tumors. CT-guided biopsy had a 23% false-negative rate and a 78% negative predictive value.

Benign tumors with interval growth or de novo presentation remain a diagnostic challenge. VDT alone is insufficient for distinguishing benign from malignant tumors. Given the substantial false-negative rate of CT-guided biopsy in small lung tumors, integrating radiologic features with clinical context is essential for guiding subsequent surveillance strategies.

Figures